Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × tozasertib × Clear all
NCT00290550 2015-07-27

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Merck Sharp & Dohme LLC

Phase 2 Terminated
22 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00405054 2015-01-26

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Merck Sharp & Dohme LLC

Phase 2 Terminated
52 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡